Prana Biotechnology Limited PRAN announced today that the company has received a grant* from The Michael J. Fox Foundation to support the initiation of pre-clinical studies which precede human trials of a novel treatment for Parkinson's disease known as PBT434. Prana, a leading Australian biotechnology company, is developing a range of highly unique treatments for neurodegenerative diseases.
The funding was awarded by the well-known foundation after a highly competitive, international, peer-reviewed process. The support comes from the MJFF's 2011 Pipeline Program to support its Therapeutic Development Initiative.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in